MedTrace Logo

Transfusion Strategies for Pediatric Liver Transplantation

NCT02951013 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 488

Last updated 2021-10-14

No results posted yet for this study

Summary

The patients assigned to the restrictive group will receive transfusion once the hemoglobin concentration falls below 6.0 g per deciliter, with a target hemoglobin range of 7.5 to 8.0 g per deciliter. Patients assigned to the liberal group will receive transfusion once the hemoglobin concentration falls below 8.0 g per deciliter, with a target hemoglobin range of 9.0 to 10.0 g per deciliter.

The primary outcome: Survival rate in six months after randomization.

Secondary outcomes: Incidence of perioperative complications, including sepsis , pulmonary complications, portal vein thrombosis, hepatic artery thrombosis and transfusion-related adverse events. Intraoperative blood loss, intraoperative blood transfusion amount, postoperative blood transfusion amount in 7 days after surgery, postoperative inflammatory reaction, mechanical ventilation time in the intensive care unit, lengths of stay in the intensive care unit and the hospital，and hospitalization expenses.

Conditions

  • Pediatric Patients Who Need Liver Transplantation

Interventions

OTHER

restrictive transfusion

Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL

OTHER

liberal transfusion

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jie Tian · RenJi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
36 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-07
Primary Completion
2022-06-30
Completion
2022-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02951013 on ClinicalTrials.gov